SynthesisFrontiers in endocrinology2025
Impact of phthalate exposure on gestational diabetes mellitus: a systematic review.
Synthesis in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Research advances on the impact of gestational diabetes mellitus on offspring neurodevelopment.Diabetology & metabolic syndrome · 2026Review
- Age-Specific Association Between Urinary Phthalate Metabolites and Diabetes Mellitus: Findings from the Korean National Environmental Health Survey Cycle 4 (2018-2020).Healthcare (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Gestational Diabetes Mellitus (GDM) is a transient diabetogenic state that often leads to adverse maternal and fetal outcomes. The rising burden of exposure to endocrine-disrupting chemicals like phthalates essentially disrupts the tightly regulated endocrine system, thereby modulating the insulin signaling pathways, leading to GDM. Objective: In the present work, a systematic review was performed to examine the probable relation between maternal exposure to phthalates, as endocrine-disrupting compounds, and GDM. Methods: Relevant studies from their inception to April 2025 were identified by searching PubMed, Embase, Scopus, and Science Direct. The data were screened using the Rayyan tool, and the risk of bias was assessed using the New Castle Ottawa Scale selection tool. Results: We identified 13 studies that showed a significant presence of phthalates in the urine samples of GDM patients. 5 phthalate secondary metabolites, Monoethyl Phthalate, Monobutyl phthalate, Mono-Isobutyl Phthalate, and Monobenzyl Phthalate and the primary phthalate Di(2-ethylhexyl) Phthalate were found to be most commonly present in the urine samples of the GDM patients. Conclusion: Urinary phthalate levels can be used as a non-invasive biomarker for GDM, thereby also reducing the risk of associated adverse pregnancy outcomes. Systematic review registration: https://www.crd.york.ac.uk/prospero/, identifier CRD420251023656.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.